{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:47:12Z","timestamp":1787021232124,"version":"build-2736575974"},"reference-count":69,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Continuum"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1212\/con.0000000000000245","type":"journal-article","created":{"date-parts":[[2015,12,4]],"date-time":"2015-12-04T04:34:17Z","timestamp":1449203657000},"page":"1577-1598","source":"Crossref","is-referenced-by-count":9,"title":["Central Nervous System Infections With Immunomodulatory Therapies"],"prefix":"10.1212","volume":"21","author":[{"given":"Eric M. L.","family":"Williamson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph R.","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"crossref","unstructured":"Nath A Berger JR. Complications of immunosuppressive\/immunomodulatory therapy in neurological diseases. Curr Treat Options Neurol 2012; 14 (3): 241\u2013255. doi:10.1007\/s11940-012-0172-y.","DOI":"10.1007\/s11940-012-0172-y"},{"key":"e_1_3_1_3_2","doi-asserted-by":"crossref","unstructured":"Cohen JA Barkhof F Comi G et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010; 362 (5): 402\u2013415. doi:10.1056\/NEJMoa0907839.","DOI":"10.1056\/NEJMoa0907839"},{"key":"e_1_3_1_5_2","unstructured":"U.S. Department of Health & Human Services. Staying healthy with AIDS: opportunistic infections. www.aids.gov\/hiv-aids-basics\/staying-healthy-with-hiv-aids\/potential-related-health-problems\/opportunistic-infections\/. Updated November 16 2010. Accessed September 30 2015."},{"key":"e_1_3_1_6_2","unstructured":"Gilenya [package insert]. Stein Switzerland: Novartis Pharma Stein AG 2015."},{"key":"e_1_3_1_7_2","doi-asserted-by":"crossref","unstructured":"Schweingruber N Reichardt SD Luhder F Reichardt HM. Mechanisms of glucocorticoids in the control of neuroinflammation. J Neuroendocrinol 2012; 24 (1): 174\u2013182. doi:10.1111\/j.1365-2826.2011.02161.x.","DOI":"10.1111\/j.1365-2826.2011.02161.x"},{"key":"e_1_3_1_8_2","doi-asserted-by":"crossref","unstructured":"Klein NC Go CH Cunha BA. Infections associated with steroid use. Infect Dis Clin North Am 2001; 15 (2): 423\u2013432 viii.","DOI":"10.1016\/S0891-5520(05)70154-9"},{"key":"e_1_3_1_10_2","doi-asserted-by":"crossref","unstructured":"Chahin S Berger JR. A risk classification for immunosuppressive treatment-associated progressive multifocal leukoencephalopathy (published online ahead of print November 18 2014). J Neurovirol. doi:10.1007\/s13365-014-0303-1.","DOI":"10.1007\/s13365-014-0303-1"},{"key":"e_1_3_1_11_2","doi-asserted-by":"crossref","unstructured":"Fine AJ Sorbello A Kortepeter C Scarazzini L. Central nervous system herpes simplex and varicella zoster virus infections in natalizumab-treated patients. Clin Infect Dis 2013; 57 (6): 849\u2013852. doi:10.1093\/cid\/cit376.","DOI":"10.1093\/cid\/cit376"},{"key":"e_1_3_1_12_2","doi-asserted-by":"crossref","unstructured":"Fragoso YD Brooks JB Gomes S et al. Report of three cases of herpes zoster during treatment with natalizumab. CNS Neurosci Ther 2013; 19 (4): 280\u2013281. doi:10.1111\/cns.12067.","DOI":"10.1111\/cns.12067"},{"key":"e_1_3_1_13_2","doi-asserted-by":"crossref","unstructured":"Kwiatkowski A Gallois J Bilbault N et al. Herpes encephalitis during natalizumab treatment in multiple sclerosis. Mult Scler 2012; 18 (6): 909\u2013911. doi:10.1177\/1352458511428082.","DOI":"10.1177\/1352458511428082"},{"key":"e_1_3_1_14_2","doi-asserted-by":"crossref","unstructured":"Shenoy ES Mylonakis E Hurtado RM Venna N. Natalizumab and HSV meningitis. J Neurovirol 2011; 17 (3): 288\u2013290. doi:10.1007\/s13365-011-0027-4.","DOI":"10.1007\/s13365-011-0027-4"},{"key":"e_1_3_1_16_2","unstructured":"Richardson EJ. Progressive multifocal leukoencephalopathy. In: Vinken P Bruyn G eds. Handbook of clinical neurology. New York: Elsevier 1970: 485\u2013499."},{"key":"e_1_3_1_17_2","doi-asserted-by":"crossref","unstructured":"Yousry TA Pelletier D Cadavid D et al. Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol 2012; 72 (5): 779\u2013787. doi:10.1002\/ana.23676.","DOI":"10.1002\/ana.23676"},{"key":"e_1_3_1_19_2","doi-asserted-by":"crossref","unstructured":"Kothary N Diak IL Brinker A et al. Progressive multifocal leukoencephalopathy associated with efalizumab use in psoriasis patients. J Am Acad Dermatol 2011; 65 (3): 546\u2013551. doi:10.1016\/j.jaad.2010.05.033.","DOI":"10.1016\/j.jaad.2010.05.033"},{"key":"e_1_3_1_20_2","doi-asserted-by":"crossref","unstructured":"Grinyo J Charpentier B Pestana JM et al. An integrated safety profile analysis of belatacept in kidney transplant recipients. Transplantation 2010; 90 (12): 1521\u20131527. doi:10.1097\/TP.0b013e3182007b95.","DOI":"10.1097\/TP.0b013e3182007b95"},{"key":"e_1_3_1_21_2","doi-asserted-by":"crossref","unstructured":"Nived O Bengtsson AA Jonsen A Sturfelt G. Progressive multifocal leukoencephalopathy\u2014the importance of early diagnosis illustrated in four cases. Lupus 2008; 17 (11): 1036\u20131041. doi:10.1177\/0961203308089445.","DOI":"10.1177\/0961203308089445"},{"key":"e_1_3_1_22_2","doi-asserted-by":"crossref","unstructured":"Giannecchini S Clausi V Vultaggio A et al. Assessment of the risk of polyomavirus JC reactivation in patients with immune-mediated diseases during long-term treatment with infliximab. J Neurovirol 2012; 18 (1): 55\u201361. doi:10.1007\/s13365-012-0078-1.","DOI":"10.1007\/s13365-012-0078-1"},{"key":"e_1_3_1_23_2","doi-asserted-by":"crossref","unstructured":"Keene DL Legare C Taylor E et al. Monoclonal antibodies and progressive multifocal leukoencephalopathy. Can J Neurol Sci 2011; 38 (4): 565\u2013571. doi:10.1017\/S0317167100012105.","DOI":"10.1017\/S0317167100012105"},{"key":"e_1_3_1_24_2","doi-asserted-by":"crossref","unstructured":"Martin SI Marty FM Fiumara K et al. Infectious complications associated with alemtuzumab use for lymphoproliferative disorders. Clin Infect Dis 2006; 43 (1): 16\u201324. doi:10.1086\/504811.","DOI":"10.1086\/504811"},{"key":"e_1_3_1_25_2","doi-asserted-by":"crossref","unstructured":"Neff RT Hurst FP Falta EM et al. Progressive multifocal leukoencephalopathy and use of mycophenolate mofetil after kidney transplantation. Transplantation 2008; 86 (10): 1474\u20131478. doi:10.1097\/TP.0b013e31818b62c8.","DOI":"10.1097\/TP.0b013e31818b62c8"},{"key":"e_1_3_1_26_2","doi-asserted-by":"crossref","unstructured":"Bonavita S Conforti R Russo A et al. Infratentorial progressive multifocal leukoencephalopathy in a patient treated with fludarabine and rituximab. Neurol Sci 2008; 29 (1): 37\u201339. doi:10.1007\/s10072-008-0857-x.","DOI":"10.1007\/s10072-008-0857-x"},{"key":"e_1_3_1_27_2","doi-asserted-by":"crossref","unstructured":"Rahmlow M Shuster EA Dominik J et al. Leflunomide-associated progressive multifocal leukoencephalopathy. Arch Neurol 2008; 65 (11): 1538\u20131539. doi:10.1001\/archneur.65.11.1538.","DOI":"10.1001\/archneur.65.11.1538"},{"key":"e_1_3_1_28_2","unstructured":"Kern RZ. Dear healthcare provider. East Hanover NJ: Novartis 2015."},{"key":"e_1_3_1_29_2","unstructured":"Putzki N Clifford DB Bischof D et al. Characteristics of PML cases in multiple sclerosis patients switching to fingolimod (FTY) from natalizumab (NTZ). Boston MA: ACTRIMS-ECTRIMS 2014: 43."},{"key":"e_1_3_1_30_2","unstructured":"Kern R. Important Gilenya safety update. East Hanover NJ: Novartis 2015."},{"key":"e_1_3_1_31_2","unstructured":"BiogenIdec. Tecfidera [package insert]. Cambridge MA: BiogenIdec 2014."},{"key":"e_1_3_1_32_2","doi-asserted-by":"crossref","unstructured":"Ermis U Weis J Schulz JB. PML in a patient treated with fumaric acid. N Engl J Med 2013; 368 (17): 1657\u20131658. doi:10.1056\/NEJMc1211805.","DOI":"10.1056\/NEJMc1211805"},{"key":"e_1_3_1_33_2","doi-asserted-by":"crossref","unstructured":"Ermis U Weis J Schulz JB. Case reports of PML in patients treated for psoriasis. N Engl J Med 2013; 369 (11): 1081. doi:10.1056\/NEJMc1307680.","DOI":"10.1056\/NEJMc1307680"},{"key":"e_1_3_1_34_2","doi-asserted-by":"crossref","unstructured":"Mrowietz U Reich K. Case reports of PML in patients treated for psoriasis. N Engl J Med 2013; 369 (11): 1080\u20131081. doi:10.1056\/NEJMc1307680#SA1.","DOI":"10.1056\/NEJMc1307680"},{"key":"e_1_3_1_35_2","doi-asserted-by":"crossref","unstructured":"van Oosten BW Killestein J Barkhof F et al. PML in a patient treated with dimethyl fumarate from a compounding pharmacy. N Engl J Med 2013; 368 (17): 1658\u20131659. doi:10.1056\/NEJMc1215357.","DOI":"10.1056\/NEJMc1215357"},{"key":"e_1_3_1_36_2","doi-asserted-by":"crossref","unstructured":"Fox EJ. Alemtuzumab in the treatment of relapsing-remitting multiple sclerosis. Expert Rev Neurother 2010; 10 (12): 1789\u20131797. doi:10.1586\/ern.10.135.","DOI":"10.1586\/ern.10.135"},{"key":"e_1_3_1_37_2","doi-asserted-by":"crossref","unstructured":"Klotz L Meuth SG Wiendl H. Immune mechanisms of new therapeutic strategies in multiple sclerosis\u2014a focus on alemtuzumab. Clin Immunol 2012; 142 (1): 25\u201330. doi:10.1016\/j.clim.2011.04.006.","DOI":"10.1016\/j.clim.2011.04.006"},{"key":"e_1_3_1_38_2","doi-asserted-by":"crossref","unstructured":"37 Keene DL Legare C Taylor E et al. Monoclonal antibodies and progressive multifocal leukoencephalopathy. Can J Neurol Sci 2011; 38 (4): 565\u2013571.","DOI":"10.1017\/S0317167100012105"},{"key":"e_1_3_1_39_2","doi-asserted-by":"crossref","unstructured":"Waggoner J Martinu T Palmer SM. Progressive multifocal leukoencephalopathy following heightened immunosuppression after lung transplant. J Heart Lung Transplant 2009; 28 (4): 395\u2013398. doi:10.1016\/j.healun.2008.12.010.","DOI":"10.1016\/j.healun.2008.12.010"},{"key":"e_1_3_1_40_2","doi-asserted-by":"crossref","unstructured":"Zaheer F Berger JR. Treatment-related progressive multifocal leukoencephalopathy: current understanding and future steps. Ther Adv Drug Saf 2012; 3 (5): 227\u2013239. doi:10.1177\/2042098612453849.","DOI":"10.1177\/2042098612453849"},{"key":"e_1_3_1_41_2","doi-asserted-by":"crossref","unstructured":"Warnatz K Peter HH Schumacher M et al. Infectious CNS disease as a differential diagnosis in systemic rheumatic diseases: three case reports and a review of the literature. Ann Rheum Dis 2003; 62 (1): 50\u201357. doi:10.1136\/ard.62.1.50.","DOI":"10.1136\/ard.62.1.50"},{"key":"e_1_3_1_42_2","doi-asserted-by":"crossref","unstructured":"Calabrese LH Molloy ES Huang D Ransohoff RM. Progressive multifocal leukoencephalopathy in rheumatic diseases: evolving clinical and pathologic patterns of disease. Arthritis Rheum 2007; 56 (7): 2116\u20132128. doi:10.1002\/art.22657.","DOI":"10.1002\/art.22657"},{"key":"e_1_3_1_43_2","doi-asserted-by":"crossref","unstructured":"Confavreux C Li DK Freedman MS et al. Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years. Mult Scler 2012; 18 (9): 1278\u20131289. doi:10.1177\/1352458512436594.","DOI":"10.1177\/1352458512436594"},{"key":"e_1_3_1_45_2","doi-asserted-by":"crossref","unstructured":"Sweetser MT Dawson KT Bozic C. Manufacturer\u2019s response to case reports of PML. N Engl J Med 2013; 368 (17): 1659\u20131661. doi:10.1056\/NEJMc1300283.","DOI":"10.1056\/NEJMc1300283"},{"key":"e_1_3_1_46_2","doi-asserted-by":"crossref","unstructured":"Rubant SA Ludwig RJ Diehl S et al. Dimethylfumarate reduces leukocyte rolling in vivo through modulation of adhesion molecule expression. J Invest Dermatol 2008; 128 (2): 326\u2013331. doi:10.1038\/sj.jid.5700996.","DOI":"10.1038\/sj.jid.5700996"},{"key":"e_1_3_1_47_2","doi-asserted-by":"crossref","unstructured":"Nieuwkamp DJ Murk JL van Oosten BW et al.: PML in a patient without severe lymphocytopenia receiving dimethyl fumarate. N Engl J Med. 2015; 372 (15): 1474\u20131476. doi:10.1056\/NEJMc1413724.","DOI":"10.1056\/NEJMc1413724"},{"key":"e_1_3_1_48_2","doi-asserted-by":"crossref","unstructured":"Molloy ES Calabrese LH. Progressive multifocal leukoencephalopathy in patients with rheumatic diseases: are patients with systemic lupus erythematosus at particular risk? Autoimmun Rev 2008; 8 (2): 144\u2013146. doi:10.1016\/j.autrev.2008.07.006.","DOI":"10.1016\/j.autrev.2008.07.006"},{"key":"e_1_3_1_49_2","doi-asserted-by":"crossref","unstructured":"Carson KR Evens AM Richey EA et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009; 113 (20): 4834\u20134840. doi:10.1182\/blood-2008-10-186999.","DOI":"10.1182\/blood-2008-10-186999"},{"key":"e_1_3_1_50_2","doi-asserted-by":"crossref","unstructured":"Frohman EM Monaco MC Remington G et al. JC virus in CD34+ and CD19+ cells in patients with multiple sclerosis treated with natalizumab. JAMA Neurol 2014; 71 (5): 596\u2013602. doi:10.1001\/jamaneurol.2014.63.","DOI":"10.1001\/jamaneurol.2014.63"},{"key":"e_1_3_1_52_2","doi-asserted-by":"crossref","unstructured":"Clifford DB De Luca A Simpson DM et al. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 2010; 9 (4): 438\u2013446. doi:10.1016\/S1474-4422(10)70028-4.","DOI":"10.1016\/S1474-4422(10)70028-4"},{"key":"e_1_3_1_53_2","doi-asserted-by":"crossref","unstructured":"Carson KR Bennett CL. Rituximab and progressive multi-focal leukoencephalopathy: the jury is deliberating. Leuk Lymphoma 2009; 50 (3): 323\u2013324. doi:10.1080\/10428190902779257.","DOI":"10.1080\/10428190902779257"},{"key":"e_1_3_1_54_2","doi-asserted-by":"crossref","unstructured":"Tan K Roda R Ostrow L et al. PML-IRIS in patients with HIV infection. Clinical manifestations and treatment with steroids. Neurology 2009; 72 (17): 1458\u20131464. doi:10.1212\/01.wnl.0000343510.08643.74.","DOI":"10.1212\/01.wnl.0000343510.08643.74"},{"key":"e_1_3_1_55_2","doi-asserted-by":"crossref","unstructured":"Berger JR Houff SA Gurwell J et al. JC virus antibody status underestimates infection rates. Ann Neurol 2013; 74 (1): 84\u201390. doi:10.1002\/ana.23893.","DOI":"10.1002\/ana.23893"},{"key":"e_1_3_1_56_2","doi-asserted-by":"crossref","unstructured":"Plavina T Subramanyam M Bloomgren G et al. Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol 2014; 76 (6): 802\u2013812. doi:10.1002\/ana.24286.","DOI":"10.1002\/ana.24286"},{"key":"e_1_3_1_57_2","unstructured":"BiogenIdec. Tysabri prescribing information and safety update. 2014."},{"key":"e_1_3_1_58_2","doi-asserted-by":"crossref","unstructured":"Kappos L Radue EW O\u2019Connor P et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010; 362 (5): 387\u2013401. doi:10.1056\/NEJMoa0909494.","DOI":"10.1056\/NEJMoa0909494"},{"key":"e_1_3_1_59_2","doi-asserted-by":"crossref","unstructured":"Kappos L Antel J Comi G et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 2006; 355 (11): 1124\u20131140. doi:10.1056\/NEJMoa052643.","DOI":"10.1056\/NEJMoa052643"},{"key":"e_1_3_1_60_2","doi-asserted-by":"crossref","unstructured":"Francis G Kappos L O\u2019Connor P et al. Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy. Mult Scler 2014; 20 (4): 471\u2013480. doi:10.1177\/1352458513500551.","DOI":"10.1177\/1352458513500551"},{"key":"e_1_3_1_61_2","doi-asserted-by":"crossref","unstructured":"Pfender N Jelcic I Linnebank M et al. Reactivation of herpesvirus under fingolimod: a case of severe herpes simplex encephalitis. Neurology 2015; 84 (23): 2377\u20132378. doi:10.1212\/WNL.0000000000001659.","DOI":"10.1212\/WNL.0000000000001659"},{"key":"e_1_3_1_62_2","unstructured":"Genzyme. Lemtrada [package insert]. Cambridge MA: Genzyme 2015."},{"key":"e_1_3_1_63_2","doi-asserted-by":"crossref","unstructured":"Bourdette D Gilden D. Fingolimod and multiple sclerosis: four cautionary tales. Neurology 2012; 79 (19): 1942\u20131943. doi:10.1212\/WNL.0b013e3182735edf.","DOI":"10.1212\/WNL.0b013e3182735edf"},{"key":"e_1_3_1_64_2","doi-asserted-by":"crossref","unstructured":"Bourre B Lefaucheur R Ahtoy P et al. Varicella-zoster virus acute myelitis in a patient with MS treated with natalizumab. Neurology 2013; 81 (22): 1966\u20131967. doi:10.1212\/01.wnl.0000439052.05262.1d.","DOI":"10.1212\/01.wnl.0000439052.05262.1d"},{"key":"e_1_3_1_65_2","doi-asserted-by":"crossref","unstructured":"Yeung J Cauquil C Saliou G et al. Varicella-zoster virus acute myelitis in a patient with MS treated with natalizumab. Neurology 2013; 80 (19): 1812\u20131813. doi:10.1212\/WNL.0b013e3182918d27.","DOI":"10.1212\/WNL.0b013e3182918d27"},{"key":"e_1_3_1_66_2","doi-asserted-by":"crossref","unstructured":"Uccelli A Ginocchio F Mancardi GL Bassetti M. Primary varicella zoster infection associated with fingolimod treatment. Neurology 2011; 76 (11): 1023\u20131024. doi:10.1212\/WNL.0b013e31821043b5.","DOI":"10.1212\/WNL.0b013e31821043b5"},{"key":"e_1_3_1_67_2","doi-asserted-by":"crossref","unstructured":"Ferraro D De Biasi S Vitetta F et al. Recurrent varicella following steroids and fingolimod in a multiple sclerosis patient. J Neuroimmune Pharmacol 2013; 8 (5): 1059\u20131061. doi:10.1007\/s11481-013-9510-4.","DOI":"10.1007\/s11481-013-9510-4"},{"key":"e_1_3_1_68_2","doi-asserted-by":"crossref","unstructured":"Ratchford JN Costello K Reich DS Calabresi PA. Varicella-zoster virus encephalitis and vasculopathy in a patient treated with fingolimod. Neurology 2012; 79 (19): 2002\u20132004. doi:10.1212\/WNL.0b013e3182735d00.","DOI":"10.1212\/WNL.0b013e3182735d00"},{"key":"e_1_3_1_69_2","doi-asserted-by":"crossref","unstructured":"Arvin AM Wolinsky JS Kappos L et al. Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management. JAMA Neurol 2015; 72 (1): 31\u201339. doi:10.1001\/jamaneurol.2014.3065.","DOI":"10.1001\/jamaneurol.2014.3065"},{"key":"e_1_3_1_70_2","doi-asserted-by":"crossref","unstructured":"Tyler KL. Fingolimod and risk of varicella-zoster virus infection: back to the future with an old infection and a new drug. JAMA Neurol 2015; 72 (1): 10\u201313. doi:10.1001\/jamaneurol.2014.3390.","DOI":"10.1001\/jamaneurol.2014.3390"},{"key":"e_1_3_1_71_2","unstructured":"Novartis. Gilenya PML healthcare provider letter. East Hanover NJ: Novartis 2015: 4."},{"key":"e_1_3_1_72_2","doi-asserted-by":"crossref","unstructured":"Issa NP Hentati A. VZV encephalitis that developed in an immunized patient during fingolimod therapy. Neurology 2015; 84 (1): 99\u2013100. doi:10.1212\/WNL.0000000000001109.","DOI":"10.1212\/WNL.0000000000001109"},{"key":"e_1_3_1_73_2","doi-asserted-by":"crossref","unstructured":"Thwaites G Fisher M Hemingway C et al. British Infection Society guidelines for the diagnosis and treatment of tuberculosis of the central nervous system in adults and children. J Infect 2009; 59 (3): 167\u2013187. doi:10.1016\/j.jinf.2009.06.011.","DOI":"10.1016\/j.jinf.2009.06.011"},{"key":"e_1_3_1_74_2","doi-asserted-by":"crossref","unstructured":"Keane J. TNF-blocking agents and tuberculosis: new drugs illuminate an old topic. Rheumatology (Oxford) 2005; 44 (6): 714\u2013720. doi:10.1093\/rheumatology\/keh567.","DOI":"10.1093\/rheumatology\/keh567"},{"key":"e_1_3_1_76_2","doi-asserted-by":"crossref","unstructured":"O\u2019Connor PW Li D Freedman MS et al. A phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology 2006; 66 (6): 894\u2013900. doi:10.1212\/01.wnl.0000203121.04509.31.","DOI":"10.1212\/01.wnl.0000203121.04509.31"},{"key":"e_1_3_1_77_2","unstructured":"Genzyme. Aubagio prescribing information. Cambridge MA: Genzyme 2015."}],"container-title":["Continuum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1212\/CON.0000000000000245","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T14:10:13Z","timestamp":1752156613000},"score":1,"resource":{"primary":{"URL":"https:\/\/continuum.aan.com\/doi\/10.1212\/CON.0000000000000245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":69,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["10.1212\/CON.0000000000000245"],"URL":"https:\/\/doi.org\/10.1212\/con.0000000000000245","relation":{},"ISSN":["1080-2371","1538-6899"],"issn-type":[{"value":"1080-2371","type":"print"},{"value":"1538-6899","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12]]}}}